National Institute on Drug Abuse; Notice of Closed Meetings, 38037 [E9-18017]
Download as PDF
Federal Register / Vol. 74, No. 145 / Thursday, July 30, 2009 / Notices
Contact: Shelly Hara, Substance
Abuse and Mental Health Services
Administration, 1 Choke Cherry Road,
Room 8–1081, Rockville, MD 20857;
telephone: (240) 276–2321; E-mail:
shelly.hara@samhsa.hhs.gov.
Dated: July 24, 2009.
Toian Vaughn,
Committee Management Officer, Substance
Abuse and Mental Health, Services
Administration.
[FR Doc. E9–18187 Filed 7–29–09; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
erowe on DSK5CLS3C1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Immunobiology of
Xenotransplantation.
Date: September 18, 2009.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, 3264, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Maryam Feili-Hariri, PhD,
Scientific Review Officer, Immunology
Review Branch, Scientific Review Program,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892–7616, 301–402–5658,
haririmf@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: July 24, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–18225 Filed 7–29–09; 8:45 am]
BILLING CODE 4140–01–P
VerDate Nov<24>2008
15:34 Jul 29, 2009
Jkt 217001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA–
F Special Emphasis Panel.
Date: August 3, 2009.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6101
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Nadine Rogers, PhD,
Scientific Review Administrator, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 220, MSC
8401, 6101 Executive Boulevard, Bethesda,
MD 20892–8401, 301–402–2105,
rogersn2@nida.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Diversity-promoting Institutions’ Drug Abuse
Research Development Program.
Date: August 3, 2009.
Time: 1 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6101
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Nadine Rogers, PhD,
Scientific Review Administrator, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 220, MSC
8401, 6101 Executive Boulevard, Bethesda,
MD 20892–8401, 301–402–2105,
rogersn2@nida.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
38037
Dated: July 23, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–18017 Filed 7–29–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of meetings of the National
Diabetes and Digestive and Kidney
Diseases Advisory Council.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Diabetes and
Digestive and Kidney Diseases Advisory
Council.
Date: September 9, 2009.
Open: 8:30 a.m. to 11:45 a.m.
Agenda: To present the Director’s Report
and other scientific presentations.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 10, Bethesda, MD 20892.
Closed: 4:15 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Conference
Room 10, Bethesda, MD 20892.
Contact Person: Brent B. Stanfield, PhD,
Director, Division of Extramural Activities,
National Institute of Diabetes and Digestive
and Kidney Diseases, 6707 Democracy Blvd.,
Room 715, MSC 5452, Bethesda, MD 20892,
(301) 594–8843, stanfibr@niddk.nih.gov.
Name of Committee: National Diabetes and
Digestive and Kidney Diseases Advisory
Council Diabetes, Endocrinology, and
Metabolic Diseases Subcommittee.
E:\FR\FM\30JYN1.SGM
30JYN1
Agencies
[Federal Register Volume 74, Number 145 (Thursday, July 30, 2009)]
[Notices]
[Page 38037]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-18017]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA-F Special Emphasis Panel.
Date: August 3, 2009.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6101 Executive Boulevard,
Rockville, MD 20852 (Telephone Conference Call).
Contact Person: Nadine Rogers, PhD, Scientific Review
Administrator, Office of Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard,
Bethesda, MD 20892-8401, 301-402-2105, rogersn2@nida.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Diversity-promoting Institutions' Drug Abuse
Research Development Program.
Date: August 3, 2009.
Time: 1 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6101 Executive Boulevard,
Rockville, MD 20852 (Telephone Conference Call).
Contact Person: Nadine Rogers, PhD, Scientific Review
Administrator, Office of Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard,
Bethesda, MD 20892-8401, 301-402-2105, rogersn2@nida.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: July 23, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-18017 Filed 7-29-09; 8:45 am]
BILLING CODE 4140-01-P